TNF α signaling beholds thalidomide saga: A review of mechanistic role of TNF-α signaling under thalidomide

Syamantak Majumder, Sree Rama Chaitanya Sreedhara, Santanu Banerjee, Suvro Chatterjee

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Tumor necrosis factor alpha (TNF-α) is a pleiotropic inflammatory cytokine. The cytokine possesses both growth stimulating properties and growth inhibitory processes*and it appears to have self regulatory properties as well. Agents like etanercept and infliximab showed beneficial effects against rheumatoid arthritis by modulationg TNF-α proteins*however*these agents are largely unable to penetrate the blood-brain barrier*which severely limits their use in different conditions. Thalidomide*an inhibitor of TNF-α protein synthesis is readily capable of crossing the blood-brain barrier and thus thalidomide and its analogs are excellent candidates for use in determining the potential value of anti-TNF-α therapies in a variety of diseases. Thalidomide blocks TNF-α expression by different possible mechanisms. Down regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)*an essential transcription factor for TNF and other cytokines under thalidomide treatment leads to reduction in the TNF-α expression. Additionally*myeloid differentiation factor 88 (MyD88)*an adapter protein regulates the expression of TNF under thalidomide treatment. Thalidomide treatment also leads to destruction of TNF-α mRNA thus*reducing the total expression of TNF-α protein. Thalidomide also targets reactive oxygen species (ROS) and α1- acid glycoprotein (AGP) to regulate TNF-α. In the present review*we discuss different possible mechanism that regulates TNF-α under thalidomide treatment. Additionally*we suggest novel strategies for the future targeting combination therapies of thalidomide and its analogs with different other anti-inflammatory drug to curb TNF-α associated diseases.

Original languageEnglish (US)
Pages (from-to)1456-1467
Number of pages12
JournalCurrent Topics in Medicinal Chemistry
Volume12
Issue number13
DOIs
StatePublished - Aug 9 2012
Externally publishedYes

Fingerprint

Thalidomide
Tumor Necrosis Factor-alpha
Cytokines
Blood-Brain Barrier
Proteins
Myeloid Differentiation Factor 88
NF-kappa B
Growth
Reactive Oxygen Species
Rheumatoid Arthritis
Glycoproteins
B-Lymphocytes
Anti-Inflammatory Agents
Down-Regulation

Keywords

  • Cytokines
  • Inflammation
  • Myeloid differentiation factor 88
  • Nuclear factor kappa B
  • Thalidomide
  • Tumor necrosis factor-a

ASJC Scopus subject areas

  • Drug Discovery

Cite this

TNF α signaling beholds thalidomide saga : A review of mechanistic role of TNF-α signaling under thalidomide. / Majumder, Syamantak; Sreedhara, Sree Rama Chaitanya; Banerjee, Santanu; Chatterjee, Suvro.

In: Current Topics in Medicinal Chemistry, Vol. 12, No. 13, 09.08.2012, p. 1456-1467.

Research output: Contribution to journalReview article

Majumder, Syamantak ; Sreedhara, Sree Rama Chaitanya ; Banerjee, Santanu ; Chatterjee, Suvro. / TNF α signaling beholds thalidomide saga : A review of mechanistic role of TNF-α signaling under thalidomide. In: Current Topics in Medicinal Chemistry. 2012 ; Vol. 12, No. 13. pp. 1456-1467.
@article{9312419b1ff448e299f88b200b39a354,
title = "TNF α signaling beholds thalidomide saga: A review of mechanistic role of TNF-α signaling under thalidomide",
abstract = "Tumor necrosis factor alpha (TNF-α) is a pleiotropic inflammatory cytokine. The cytokine possesses both growth stimulating properties and growth inhibitory processes*and it appears to have self regulatory properties as well. Agents like etanercept and infliximab showed beneficial effects against rheumatoid arthritis by modulationg TNF-α proteins*however*these agents are largely unable to penetrate the blood-brain barrier*which severely limits their use in different conditions. Thalidomide*an inhibitor of TNF-α protein synthesis is readily capable of crossing the blood-brain barrier and thus thalidomide and its analogs are excellent candidates for use in determining the potential value of anti-TNF-α therapies in a variety of diseases. Thalidomide blocks TNF-α expression by different possible mechanisms. Down regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)*an essential transcription factor for TNF and other cytokines under thalidomide treatment leads to reduction in the TNF-α expression. Additionally*myeloid differentiation factor 88 (MyD88)*an adapter protein regulates the expression of TNF under thalidomide treatment. Thalidomide treatment also leads to destruction of TNF-α mRNA thus*reducing the total expression of TNF-α protein. Thalidomide also targets reactive oxygen species (ROS) and α1- acid glycoprotein (AGP) to regulate TNF-α. In the present review*we discuss different possible mechanism that regulates TNF-α under thalidomide treatment. Additionally*we suggest novel strategies for the future targeting combination therapies of thalidomide and its analogs with different other anti-inflammatory drug to curb TNF-α associated diseases.",
keywords = "Cytokines, Inflammation, Myeloid differentiation factor 88, Nuclear factor kappa B, Thalidomide, Tumor necrosis factor-a",
author = "Syamantak Majumder and Sreedhara, {Sree Rama Chaitanya} and Santanu Banerjee and Suvro Chatterjee",
year = "2012",
month = "8",
day = "9",
doi = "10.2174/156802612801784443",
language = "English (US)",
volume = "12",
pages = "1456--1467",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - TNF α signaling beholds thalidomide saga

T2 - A review of mechanistic role of TNF-α signaling under thalidomide

AU - Majumder, Syamantak

AU - Sreedhara, Sree Rama Chaitanya

AU - Banerjee, Santanu

AU - Chatterjee, Suvro

PY - 2012/8/9

Y1 - 2012/8/9

N2 - Tumor necrosis factor alpha (TNF-α) is a pleiotropic inflammatory cytokine. The cytokine possesses both growth stimulating properties and growth inhibitory processes*and it appears to have self regulatory properties as well. Agents like etanercept and infliximab showed beneficial effects against rheumatoid arthritis by modulationg TNF-α proteins*however*these agents are largely unable to penetrate the blood-brain barrier*which severely limits their use in different conditions. Thalidomide*an inhibitor of TNF-α protein synthesis is readily capable of crossing the blood-brain barrier and thus thalidomide and its analogs are excellent candidates for use in determining the potential value of anti-TNF-α therapies in a variety of diseases. Thalidomide blocks TNF-α expression by different possible mechanisms. Down regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)*an essential transcription factor for TNF and other cytokines under thalidomide treatment leads to reduction in the TNF-α expression. Additionally*myeloid differentiation factor 88 (MyD88)*an adapter protein regulates the expression of TNF under thalidomide treatment. Thalidomide treatment also leads to destruction of TNF-α mRNA thus*reducing the total expression of TNF-α protein. Thalidomide also targets reactive oxygen species (ROS) and α1- acid glycoprotein (AGP) to regulate TNF-α. In the present review*we discuss different possible mechanism that regulates TNF-α under thalidomide treatment. Additionally*we suggest novel strategies for the future targeting combination therapies of thalidomide and its analogs with different other anti-inflammatory drug to curb TNF-α associated diseases.

AB - Tumor necrosis factor alpha (TNF-α) is a pleiotropic inflammatory cytokine. The cytokine possesses both growth stimulating properties and growth inhibitory processes*and it appears to have self regulatory properties as well. Agents like etanercept and infliximab showed beneficial effects against rheumatoid arthritis by modulationg TNF-α proteins*however*these agents are largely unable to penetrate the blood-brain barrier*which severely limits their use in different conditions. Thalidomide*an inhibitor of TNF-α protein synthesis is readily capable of crossing the blood-brain barrier and thus thalidomide and its analogs are excellent candidates for use in determining the potential value of anti-TNF-α therapies in a variety of diseases. Thalidomide blocks TNF-α expression by different possible mechanisms. Down regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)*an essential transcription factor for TNF and other cytokines under thalidomide treatment leads to reduction in the TNF-α expression. Additionally*myeloid differentiation factor 88 (MyD88)*an adapter protein regulates the expression of TNF under thalidomide treatment. Thalidomide treatment also leads to destruction of TNF-α mRNA thus*reducing the total expression of TNF-α protein. Thalidomide also targets reactive oxygen species (ROS) and α1- acid glycoprotein (AGP) to regulate TNF-α. In the present review*we discuss different possible mechanism that regulates TNF-α under thalidomide treatment. Additionally*we suggest novel strategies for the future targeting combination therapies of thalidomide and its analogs with different other anti-inflammatory drug to curb TNF-α associated diseases.

KW - Cytokines

KW - Inflammation

KW - Myeloid differentiation factor 88

KW - Nuclear factor kappa B

KW - Thalidomide

KW - Tumor necrosis factor-a

UR - http://www.scopus.com/inward/record.url?scp=84864543115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864543115&partnerID=8YFLogxK

U2 - 10.2174/156802612801784443

DO - 10.2174/156802612801784443

M3 - Review article

C2 - 22650377

AN - SCOPUS:84864543115

VL - 12

SP - 1456

EP - 1467

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 13

ER -